Clopidogrel Tablet, Film Coated
Product Images NDC 68071-4023

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68071-4023). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 4023 3

This is a description for a box of 30 tablets of Clopidogrel 75mg. It includes a warning to keep the tablets out of reach of children and provides the NDC number. The tablets are film-coated and each contains 75mg of Clopidogrel base. The label advises consulting a doctor for medical advice on potential side effects and recommends storing the tablets at a controlled temperature between 68-77°F.*

FDA Label Image

Figure 1 (Clopidogrel Fig1)

This text describes a figure showing the exposure to Clopidogrel Active Metabolite after the administration of multiple doses of Clopidogrel Bisulfate 75 mg alone or with Proton Pump Inhibitors (PPIs). It includes information on the co-administered PPIs and their effects on the active metabolite AUC, along with changes relative to Clopidogrel bisulfate administered alone. The figure provides data on the mean and 90% confidence interval for each PPI.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

This text displays the Cumulative Event Rate (%) for different time points (1-12 months) of follow-up in a study comparing Plagebo (placebo + aspirin) with Clopidogrel Bisulfate (Clopidogrel + aspirin) for preventing cardiovascular death, myocardial infarction, and stroke. The data shows a statistically significant difference between the two groups, with a p-value of 0.00009. Other standard therapies were also used in the study.*

FDA Label Image

Figure 3: Hazard Ratio For Patient Baseline Characteristics And On-study Concomitant Medications/interventions For The Cure Study (Clopidogrel Fig3)

The text appears to be a table containing medical information related to cardiovascular conditions such as diabetes, myocardial infarction (MI), stroke, and various medications like Heparin, Aspirin, Clopidogrel, Beta Blockers, and GP IIb/IIIa Antagonists. The table also includes statistical data presented in numerical values and percentages, showing outcomes favoring treatment or placebo. The Hazard Ratio (HR) values seem to be shown but the confidence intervals (CI) are missing. This comprehensive medical data seems to be part of a clinical study or research on cardiovascular treatments and outcomes.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

This information shows a comparison of mortality rates between a placebo group and a group receiving Clopidogrel medication after the first discharge. The placebo group had 1845 deaths, representing 8.1% of the participants, while the Clopidogrel group had 1726 deaths, accounting for 7.5% of the participants. The data indicates a 7% proportional risk reduction in mortality among individuals receiving Clopidogrel (p = 0.03). The study tracked the mortality rates over a period of up to 28 days since randomization.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

This text provides data on the comparison of two treatments, Placebo (2310 subjects with an event rate of 10.1%) and Clopidogrel (2121 subjects with an event rate of 9.2%). The analysis shows a 9% proportional risk reduction in mortality, re-infarction, or stroke, with a p-value of 0.002. The outcomes are tracked over 28 days post-randomization.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

This is a data table showing information related to different subgroups divided by gender, age, time since onset, blood pressure, heart rate, fibrinolytic agent given, and use of Clopidogrel Bisulfate. The table includes percentages, counts, and odds ratios with confidence intervals for different variables.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

This is a table showing the cumulative event rate (%) for fatal or non-fatal vascular events over 36 months of follow-up for patients taking Aspirin and Clopidogrel Bisultate. This information may be used to analyze the effectiveness of these medications in preventing such events.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

This data provides information on patients with qualifying conditions such as Stroke, Mi (Myocardial infarction), and PAD (Peripheral Artery Disease) who were treated with Clopidogrel Bisulfate and Aspirin. The numbers indicate the count of patients in each category, with percentages of total. The table also suggests the hazard ratio favoring Clopidogrel Bisulfate over Aspirin. This information is useful for understanding the comparison of effectiveness between the two medications in these specific medical conditions.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.